Skip to main content
. 2021 Apr 8;7(4):280. doi: 10.3390/jof7040280

Table 1.

Clinical profiles of patients with COVID-19-associated candidemia admitted to COVID-19 intensive care units of two hospitals in Mashhad, Iran, from November 2020 to late January 2021.

Patient # Age/Sex CVC BA PTN MV ID Surgery UD HD (Days) DTCD Yeast Species (Isolate #) AFT * Outcome
P94 70/F Yes Yes Yes Yes No Brain surgery Hematological malignancy 56 51 C. glabrata (#94) Fluconazole→Caspofungin Died
P98 40/M Yes Yes Yes Yes No No None 83 2 7 C. albicans (#98) Fluconazole Died
P110 28/F Yes Yes Yes Yes No No None 45 6 C. albicans (#110) Fluconazole→Caspofungin Died
C. albicans (#111)
P112 68/F Yes Yes Yes Yes No No None 6 31 R. mucilaginosa (#112) CVC removal + Fluconazole Survived
P121 69/F Yes Yes Yes Yes No No Endocervical cancer, diabetes 22 4 C. glabrata (#121) Fluconazole→Caspofungin Died
C. glabrata (#122)
P123 27/M Yes Yes Yes No No No None 17 5 C. albicans (#123) Fluconazole→Caspofungin Died
P124 75/M Yes Yes Yes Yes No No Ovarian cancer 7 1 C. albicans (#124) Fluconazole→Caspofungin Died

* The loading doses for fluconazole and caspofungin, 800 and 70 mg/day, were de-escalated to 400 and 50 mg/day, respectively. The data on the duration of antifungal treatment were not available. CVC, central venous catheter; BA, broad-spectrum antibiotics; PTN, parenteral nutrition; MV, mechanical ventilation; ID, immunosuppressive drug; HD, hospitalization duration; UD, underlying diseases; DTCD, days to candidemia diagnosis; AFT, antifungal treatment.